Medical interventions for traumatic hyphema.
BACKGROUND
Traumatic hyphema is the entry of blood into the anterior chamber (the space between the cornea and iris) subsequent to a blow or a projectile striking the eye. Hyphema uncommonly causes permanent loss of vision. Associated trauma (e.g., corneal staining, traumatic cataract, angle recession glaucoma, optic atrophy, etc.) may seriously affect vision. Such complications may lead to permanent impairment of vision. Patients with sickle cell trait/disease may be particularly susceptible to increases of elevated intraocular pressure. If rebleeding occurs, the rates and severity of complications increase.


OBJECTIVE
The objective of this review was to assess the effectiveness of various medical interventions in the management of traumatic hyphema.


METHODS
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2010, Issue 6), MEDLINE (January 1950 to June 2010), EMBASE (January 1980 to June 2010), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com) and ClinicalTrials.gov (http://clinicaltrials.gov). We searched the reference lists of identified trial reports to find additional trials. We also searched the ISI Web of Science Social Sciences Citation Index (SSCI) to find studies that cited the identified trials. There were no language or date restrictions in the search for trials. The electronic databases were last searched on 25 June 2010.


METHODS
Two authors independently assessed the titles and abstracts of all reports identified by the electronic and manual searches. In this review, we included randomized and quasi-randomized trials that compared various medical interventions to other medical interventions or control groups for the treatment of traumatic hyphema following closed globe trauma. There were no restrictions regarding age, gender, severity of the closed globe trauma or level of visual acuity at the time of enrollment.


METHODS
Two authors independently extracted the data for the primary and secondary outcomes. We entered and analyzed data using Review Manager (RevMan) 5. We performed meta-analyses using a fixed-effect model and reported dichotomous outcomes as odds ratios and continuous outcomes as mean differences.


RESULTS
Nineteen randomized and seven quasi-randomized studies with 2,560 participants were included in this review. Interventions included antifibrinolytic agents (oral and systemic aminocaproic acid, tranexamic acid, and aminomethylbenzoic acid), corticosteroids (systemic and topical), cycloplegics, miotics, aspirin, conjugated estrogens, monocular versus bilateral patching, elevation of the head, and bed rest. No intervention had a significant effect on visual acuity whether measured at two weeks or less after the trauma or at longer time periods. The number of days for the primary hyphema to resolve appeared to be longer with the use of aminocaproic acid compared to no use, but was not altered by any other intervention.Systemic aminocaproic acid reduced the rate of recurrent hemorrhage (odds ratio (OR) 0.25, 95% confidence interval (CI) 0.11 to 0.5), but a sensitivity analysis omitting studies not using an intention-to-treat (ITT) analysis reduced the strength of the evidence (OR 0.41, 95% CI 0.16 to 1.09). We obtained similar results for topical aminocaproic acid (OR 0.42, 95% CI 0.16 to 1.10). We found tranexamic acid had a significant effect in reducing the rate of secondary hemorrhage (OR 0.25, 95% CI 0.13 to 0.49), as did aminomethylbenzoic acid as reported in a single study (OR 0.07, 95% CI 0.01 to 0.32). The evidence to support an associated reduction in the risk of complications from secondary hemorrhage (i.e., corneal blood staining, peripheral anterior synechiae, elevated intraocular pressure, and development of optic atrophy) by antifibrinolytics was limited by the small number of these events. Use of aminocaproic acid was associated with increased nausea, vomiting, and other adverse events compares with placebo. We found no difference in the number of adverse events with the use of systemic versus topical aminocaproic acid or with standard versus lower drug dose. The available evidence on usage of corticosteroids, cycloplegics or aspirin in traumatic hyphema was limited due to the small numbers of participants and events in the trials.We found no difference in effect between a single versus binocular patch nor ambulation versus complete bed rest on the risk of secondary hemorrhage or time to rebleed.


CONCLUSIONS
Traumatic hyphema in the absence of other intraocular injuries, uncommonly leads to permanent loss of vision. Complications resulting from secondary hemorrhage could lead to permanent impairment of vision, especially in patients with sickle cell trait/disease. We found no evidence to show an effect on visual acuity by any of the interventions evaluated in this review. Although evidence is limited, it appears that patients with traumatic hyphema who receive aminocaproic acid or tranexamic acid are less likely to experience secondary hemorrhaging. However, hyphema in patients on aminocaproic acid take longer to clear.Other than the possible benefits of antifibrinolytic usage to reduce the rate of secondary hemorrhage, the decision to use corticosteroids, cycloplegics, or non-drug interventions (such as binocular patching, bed rest, or head elevation) should remain individualized because no solid scientific evidence supports a benefit. As these multiple interventions are rarely used in isolation, further research to assess the additive effect of these interventions might be of value.
Department of Special Surgery-Ophthalmology, Faculty of Medicine, The University of Jordan, P.O. Box 13046, Amman, Jordan.
Almutez
A
Gharaibeh
Howard I
HI
Savage
Roberta W
RW
Scherer
Morton F
MF
Goldberg
Kristina
K
Lindsley
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D015119:Aminocaproic Acid / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001458:Bandages; D001510:Bed Rest; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use; D006801:Humans; D006988:Hyphema / Q000209:etiology / Q000628:therapy*; D009184:Mydriatics / Q000627:therapeutic use; D056888:Patient Positioning / Q000379:methods; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D014949:Wounds, Nonpenetrating / Q000150:complications*
D000305:Adrenal Cortex Hormones; D000933:Antifibrinolytic Agents; D004966:Estrogens, Conjugated (USP); D009184:Mydriatics; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin; D015119:Aminocaproic Acid
Vestn Oftalmol. 1972;1:41-5
5016810
Vestn Oftalmol. 1971 Nov-Dec;6:43-6
5144435
Vopr Med Khim. 1985 Jul-Aug;31(4):47-51
4049786
Haemostasis. 1982;11(4):235-41
6982199
Harefuah. 1990 Nov 1;119(9):269-70
2258114
S Afr Med J. 1971 Nov 13;45(44):1250-2
5133221
Boll Chim Farm. 1981 Mar;120(3):156-8
7272018
Ann Ophthalmol. 1988 Apr;20(4):157-8
3288070
Trans Ophthalmol Soc U K. 1966;86:843-5
5226618
Ophthalmology. 1999 Feb;106(2):375-9
9951493
Acta Ophthalmol (Copenh). 1978 Oct;56(5):763-8
696263
Acta Ophthalmol (Copenh). 1972;50(4):549-55
4678274
Arch Ophthalmol. 1983 Jul;101(7):1031-3
6870623
Vestn Oftalmol. 1991 Nov-Dec;107(6):34-6
1781121
Br J Ophthalmol. 1967 May;51(5):315-20
6022773
Eur J Ophthalmol. 2003 Jan-Feb;13(1):57-61
12635675
Acta Ophthalmol (Copenh). 1980 Oct;58(5):787-93
7211267
Ophthalmology. 1987 Oct;94(10):1232-7
3317180
Acta Ophthalmol (Copenh). 1983 Jun;61(3):447-53
6353843
Acta Ophthalmol (Copenh). 1969;47(3):784-91
5307565
Zhonghua Yan Ke Za Zhi. 1982 Mar;18(2):83-4
6807653
Acta Ophthalmol Suppl. 1980;(145):1-53
6257028
Ophthalmic Surg. 1979 Apr;10(4):17-31
460814
Ophthalmologica. 1967;154(1):31-8
4228702
J Natl Med Assoc. 1974 Nov;66(6):484-6
4436882
Ann Ophthalmol. 1990 Oct;22(10):366-8
2244716
Br J Ophthalmol. 1971 Dec;55(12):826-32
5159809
Arch Ophthalmol. 1980 Jan;98(1):116-9
7352858
Bull Soc Belge Ophtalmol. 1977 Nov 27;179:47-52
615667
Oftalmol Zh. 1985;(3):148-51
4011096
Trans Can Opthalmolog Soc. 1961;24:217-22
13898610
Arch Ophthalmol. 1984 Jun;102(6):818, 820-1
6732557
Int Ophthalmol Clin. 1995 Winter;35(1):93-103
7751138
Ophthalmic Surg. 1979 Apr;10(4):89-123
111203
Am J Ophthalmol. 1990 Jan 15;109(1):23-7
2297028
Eye Ear Nose Throat Mon. 1971 Jul;50(7):266-7
5561440
Bull Soc Belge Ophtalmol. 1981;193:77-8
7343054
Vestn Oftalmol. 2002 Sep-Oct;118(5):25-7
12532741
Trans Ophthalmol Soc U K. 1964;84:271-4
5227421
Arch Ophthalmol. 1974 Mar;91(3):190-1
4814965
Arch Ophthalmol. 1997 Sep;115(9):1106-12
9298049
Ann Ophthalmol. 1973 Dec;5(12):1297-300
4769181
Ophthalmology. 2003 Nov;110(11):2106-12
14597516
Arch Ophthalmol. 2001 Jan;119(1):64-70
11146728
Ophthalmology. 1995 Nov;102(11):1646-53
9098257
J Pediatr Ophthalmol Strabismus. 1999 Sep-Oct;36(5):238-50; quiz 279-80
10505828
Bull Soc Ophtalmol Fr. 1987 Apr;87(4):503-4
3652362
Arch Oftalmol B Aires. 1970 Nov;45(11):477-83
5513808
Ophthalmology. 1991 Mar;98(3):279-86
2023746
Vestn Oftalmol. 1966 May-Jun;79(3):19-21
4230878
Ann Ophthalmol. 1975 May;7(5):659-62, 664-6, 668-70
1137285
Am J Ophthalmol. 1972 Aug;74(2):284-92
5054238
Ophthalmologica. 1973;167(5):373-82
4771485
Am J Ophthalmol. 1964 Sep;58:479-82
14204810
J Pediatr Ophthalmol Strabismus. 1986 Mar-Apr;23(2):92-5
3790203
Arch Ophthalmol. 1960 Jun;63:1001-4
13850596
Am J Ophthalmol. 1966 Dec;62(6):1098-106
4289281
Surv Ophthalmol. 2002 Jul-Aug;47(4):297-334
12161209
Ann Ophthalmol. 1974 Oct;6(10):1016-8, 1020-1
4429308
Eye (Lond). 1993;7 ( Pt 1):155-7
8325408
Ophthalmic Surg. 1979 Apr;10(4):78-88
37471
Ugeskr Laeger. 1977 Jun 13;139(24):1422-4
878038
Arch Ophthalmol. 1987 Feb;105(2):206-8
3813951
Am J Ophthalmol. 1976 Mar;81(3):355-60
769560
Arch Ophthalmol. 1988 Sep;106(9):1207-9
3415544
Ophthalmology. 1986 Jan;93(1):102-8
3951807
J Med Libr Assoc. 2006 Apr;94(2):130-6
16636704
Am J Ophthalmol. 1973 Sep;76(3):359-62
4728562
Med J Malaysia. 1988 Jun;43(2):155-8
3237131
Ophthalmology. 1999 Feb;106(2):380-5
9951494